Ferguson Wellman Capital Management Inc. boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,255 shares of the medical research company’s stock after buying an additional 761 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $25,517,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares during the period. C WorldWide Group Holding A S raised its position in shares of Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares during the period. Veritas Asset Management LLP bought a new position in shares of Thermo Fisher Scientific during the first quarter worth $175,795,000. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after buying an additional 695,079 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Thermo Fisher Scientific by 68.8% in the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock worth $210,900,000 after buying an additional 559,400 shares during the period. Hedge funds and other institutional investors own 83.52% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE TMO) opened at 178.43 on Tuesday. The stock has a 50 day moving average of $176.80 and a 200-day moving average of $167.41. The stock has a market cap of $69.61 billion, a P/E ratio of 31.09 and a beta of 1.06. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same period last year, the business earned $2.03 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.34%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

TRADEMARK VIOLATION WARNING: “Ferguson Wellman Capital Management Inc. Has $25.52 Million Stake in Thermo Fisher Scientific Inc (TMO)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/29/ferguson-wellman-capital-management-inc-has-25-52-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

A number of equities analysts have weighed in on TMO shares. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Cantor Fitzgerald started coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 18th. They issued an “overweight” rating and a $194.00 price target on the stock. BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Barclays PLC reiterated an “overweight” rating and issued a $190.00 price target (up previously from $175.00) on shares of Thermo Fisher Scientific in a report on Tuesday, May 9th. One analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $188.56.

In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the transaction, the director now directly owns 38,757 shares of the company’s stock, valued at $6,790,226.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders sold 34,818 shares of company stock valued at $6,028,985 over the last three months. 0.49% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.